Fabrizio Calapai

Dr. Fabrizio Calapai

Phactory - Pharmaceutical Consultancy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FCFabrizio Calapai
Fabrizio Calapai
LCLuigi Cardia
Luigi Cardia
ESEmanuela Elisa Sorbara
Emanuela Elisa Sorbara
Michele NavarraMichele Navarra
Michele Navarra
SGSebastiano Gangemi
Sebastiano Gangemi
CMCarmen Mannucci
Carmen Mannucci
Potential therapeutic actions of the cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are based on their activity as analgesics, anti-emetics, anti-inflammatory agents, anti-seizure compounds. THC and CBD lipophilicity and their neurological actions makes them candidates as new medicinal approaches to treat central nervous system (CNS) diseases. However, they show differences about penetrability and disposition in the brain. The present article is an overview about THC and CBD crossing the blood–brain barrier (BBB) and their brain disposition. Several findings indicate that CBD can modify the deleterious effects on BBB caused by inflammatory cytokines and may play a pivotal role in ameliorating BBB dysfunction consequent to ischemia. Thus supporting the therapeutic potential of CBD for the treatment of ischemic and inflammatory diseases of CNS. Cannabinoids positive effects on cognitive function could be also considered through the aspect of protection of BBB cerebrovascular structure and function, indicating that they may purchase substantial benefits through the protection of BBB integrity. Delivery of these cannabinoids in the brain following different routes of administration (subcutaneous, oral, and pulmonary) is illustrated and commented. Finally, the potential role of cannabinoids in drug-resistance in the clinical management of neurological or psychiatric diseases such as epilepsy and schizophrenia is discussed on the light of their crossing the BBB.

1 January 2018 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CMCarmen Mannucci
Carmen Mannucci
FCFabrizio Calapai
Fabrizio Calapai
LCLuigi Cardia
Luigi Cardia
GIGiuseppina Inferrera
Giuseppina Inferrera
Giovanni D'ArenaGiovanni D'Arena
Giovanni D'Arena
Gioacchino CalapaiGioacchino Calapai
Gioacchino Calapai
Objective. The aim of this review is to analyze preclinical and clinical studies investigating the anxiety effects of Citrus aurantium or Citrus sinensis essential oils (EOs). Design. The bibliographic research was made on the major scientific databases. Analysis included only articles written in English and published on peer‐reviewed scientific journals describing preclinical experiments and clinical trials carried out to investigate the antianxiety effects of Citrus aurantium or Citrus sinensis EOs on anxiety disorders. Clinical studies reporting the antianxiety effects of products containing Citrus aurantium or Citrus sinensis EOs in combination with other active substances, including medicinal plants, were excluded. Nine clinical studies fulfilled the criteria adopted for analysis. Results. Data show that Citrus aurantium or Citrus sinensis EOs produce anxiolytic effects both in preclinical experiments and in different clinical conditions. Citrus aurantium EO aromatherapy reduced anxiety level in the great part of stress conditions studied (subjects affected by chronic myeloid leukemia and preoperative patients) except for a sample of patients subjected to colonoscopy. Exposition to Citrus sinensis EO in clinical studies shows to be positive in reducing anxiety level in patients waiting for dental treatment as well as in healthy volunteers submitted to an anxiogenic situation. Conclusions. Overview of clinical trials conducted with Citrus aurantium or Citrus sinensis on people with anxiety showed that inhalation or oral administration of Citrus aurantium and inhalation of Citrus sinensis can exert beneficial effects on anxiety; however, because of incomplete accuracy in the reporting of methodology, further more complete clinical studies are warranted.

17 October 2016 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
CMCarmen Mannucci
Carmen Mannucci
Michele NavarraMichele Navarra
Michele Navarra
FCFabrizio Calapai
Fabrizio Calapai
SRSqueri Raffaele
Squeri Raffaele
SGSebastiano Gangemi
Sebastiano Gangemi
Gioacchino CalapaiGioacchino Calapai
Gioacchino Calapai

10 April 2014 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
MMMarco Miroddi
Marco Miroddi
Michele NavarraMichele Navarra
Michele Navarra
MQMaria C. Quattropani
Maria C. Quattropani
FCFabrizio Calapai
Fabrizio Calapai
SGSebastiano Gangemi
Sebastiano Gangemi
Gioacchino CalapaiGioacchino Calapai
Gioacchino Calapai

1 September 2014 in Pharmacology
Verified
Journal Article
Open access
PDF file
Gioacchino CalapaiGioacchino Calapai
Gioacchino Calapai
MCMarco Casciaro
Marco Casciaro
MMMarco Miroddi
Marco Miroddi
FCFabrizio Calapai
Fabrizio Calapai
Michele NavarraMichele Navarra
Michele Navarra
SGSebastiano Gangemi
Sebastiano Gangemi
Background: Montelukast, a leucotriene receptor antagonist, binds the cysteinyl leucotriene type 1 receptor. Montelukast is commonly prescribed to asthma patients as add-on therapy to inhaled corticosteroids. Several clinical trials emphasized that montelukast can be considered a safe drug. However, recent evidence reconsidered the benefit/risk ratio of the use of montelukast for both paediatric and adult patients. Summary: The present review analyzed the previous published case reports regarding montelukast-induced adverse drug reactions (ADRs). They included agitation, anxiety, depression, sleep disturbance, hallucinations, suicidal thinking and suicidality, tremor, dizziness, drowsiness, neuropathies and seizures. The immune system can be involved, in particular, cases of Churg-Strauss syndrome have been published. Furthermore, it can induce hypersensitivity reactions, including anaphylaxis and eosinophilic infiltration. In addition, hepatobiliary, pancreatic and uropoietic disorders have been observed. Some of these cases are characterized by severe prognosis (i.e. neurological deficit and fatal hepatotoxicity). Key Message: The use of montelukast can be burdened by several ADRs, of which physicians should be aware in their clinical practice. A better understanding of the mechanisms causing ADRs after using montelukast could help researchers and clinicians in defining a risk-reduction strategy aimed to lessen montelukast toxicity. More accurate epidemiological studies, in order to discover risk factors favouring montelukast-associated ADRs, are demanded.

9 August 2017 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
CMCarmen Mannucci
Carmen Mannucci
Michele NavarraMichele Navarra
Michele Navarra
FCFabrizio Calapai
Fabrizio Calapai
ESElvira V. Spagnolo
Elvira V. Spagnolo
FBFrancesco P. Busardò
Francesco P. Busardò
GCGioacchino Calapai
Gioacchino Calapai
Background: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases. Objective: The aim of the present review was to describe the state of art about the pre-clinical research, the potential use and, when existing, the clinical evidence related to CBD in the neurological field. Method: Collection of all the pre-clinical and clinical findings carried out investigating the effects of CBD alone, not in combination with other substances, in the neurological arena with the exclusion of studies on neuropsychiatric disorders. Results: Laboratory and clinical studies on the potential role of CBD in Parkinson’s disease (PD), Alzheimer’s disease (AD), multiple sclerosis (MS), Huntington’s disease (HD), amyotrophic lateral sclerosis ALS), cerebral ischemia, were examined. Conclusion: Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies. CBD pre-clinical demonstration of antiepileptic activity is supported by recent clinical studies in human epileptic subjects resistant to standard antiepileptic drugs showing its potential use in children and young adults affected by refractory epilepsy. Evidence for use of CBD in PD is still not supported by sufficient data whereas only a few studies including a small number of patients are available.